Increased HRD score in cisplatin resistant penile cancer cells.

Humans Male Cisplatin / pharmacology Penile Neoplasms / drug therapy Drug Resistance, Neoplasm / genetics Fluorouracil / pharmacology Cell Line, Tumor Antineoplastic Combined Chemotherapy Protocols / pharmacology
Cell lines Chemoresistance Homologous recombination deficiency Penile carcinomas

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
23 Dec 2022
Historique:
received: 16 09 2022
accepted: 09 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 28 12 2022
Statut: epublish

Résumé

Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1 The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1

Sections du résumé

BACKGROUND/INTRODUCTION BACKGROUND
Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy.
METHODS METHODS
We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1
RESULTS AND CONCLUSIONS CONCLUSIONS
The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1

Identifiants

DOI: 10.1186/s12885-022-10432-7 PMID: 36564761 PMC: PMC9789628
pubmed: 36564761
doi: 10.1186/s12885-022-10432-7
pii: 10.1186/s12885-022-10432-7
pmc: PMC9789628
doi:

Substances chimiques

Cisplatin Q20Q21Q62J
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1352

Informations de copyright

© 2022. The Author(s).

Références

Cancer Res. 2007 Jul 1;67(13):6325-32
pubmed: 17616691
Cells. 2020 Jul 13;9(7):
pubmed: 32668560
Tohoku J Exp Med. 1966 Jan 25;88(1):9-20
pubmed: 5920635
Tumour Biol. 2017 Mar;39(3):1010428317695931
pubmed: 28351323
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Urol Oncol. 2018 Jan;36(1):14.e17-14.e24
pubmed: 29031418
BMC Cancer. 2013 Oct 19;13:484
pubmed: 24139550
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Clin Cancer Res. 2013 Oct 1;19(19):5320-8
pubmed: 24089445
Cancers (Basel). 2020 Feb 25;12(3):
pubmed: 32106627
J Cancer Res Clin Oncol. 2021 Apr;147(4):1125-1135
pubmed: 33635430
Keio J Med. 1989 Sep;38(3):277-93
pubmed: 2585941
Carcinogenesis. 2018 Jul 30;39(8):971-980
pubmed: 29955840
Hinyokika Kiyo. 1983 Apr;29(4):373-6
pubmed: 6587762
Virchows Arch. 2022 Jun;480(6):1159-1169
pubmed: 35024940
NPJ Precis Oncol. 2022 Jun 9;6(1):36
pubmed: 35681079
Lung Cancer. 2021 Oct;160:1-7
pubmed: 34364112
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Oncotarget. 2018 Mar 23;9(22):16074-16086
pubmed: 29662627
NPJ Breast Cancer. 2018 Jul 2;4:16
pubmed: 29978035
Sci Rep. 2020 Sep 9;10(1):14839
pubmed: 32908186
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Transl Androl Urol. 2017 Oct;6(5):791-802
pubmed: 29184775
Am J Surg Pathol. 2011 Apr;35(4):553-62
pubmed: 21399489
Oncologist. 2016 Jan;21(1):33-9
pubmed: 26670666
Signal Transduct Target Ther. 2021 Jan 11;6(1):10
pubmed: 33431788
Cancer Cell. 2012 Sep 11;22(3):373-88
pubmed: 22975379
Crit Rev Biochem Mol Biol. 2021 Apr;56(2):157-177
pubmed: 33596761
J Urol. 1992 Mar;147(3):630-2
pubmed: 1538445
BJU Int. 2015 Oct;116(4):584-9
pubmed: 25639616
Pathobiology. 2019;86(2-3):145-151
pubmed: 30650417
Cell Death Dis. 2018 Jun 7;9(6):684
pubmed: 29880898
Oncol Rep. 2010 Mar;23(3):739-44
pubmed: 20127014
Urol Int. 2009;82(1):1-7
pubmed: 19172088
Dtsch Arztebl Int. 2018 Sep 28;115(39):646-652
pubmed: 30375327
Cancer Drug Resist. 2019 Sep 19;2(3):447-456
pubmed: 35582596
Int J Mol Sci. 2021 Dec 27;23(1):
pubmed: 35008677
J Exp Clin Cancer Res. 2021 Oct 12;40(1):317
pubmed: 34641952
Hum Cell. 2022 Jan;35(1):199-213
pubmed: 34628623
Signal Transduct Target Ther. 2017 Dec 22;2:17063
pubmed: 29279775
Front Cell Dev Biol. 2020 Sep 09;8:564601
pubmed: 33015058
Cells. 2021 Apr 06;10(4):
pubmed: 33917394
Nat Commun. 2013;4:2126
pubmed: 23839242
Cell Death Dis. 2011 Dec 15;2:e243
pubmed: 22170099
Nature. 2011 Mar 10;471(7337):235-9
pubmed: 21390130
Am J Pathol. 2001 Oct;159(4):1211-8
pubmed: 11583947
Cancers (Basel). 2020 Apr 26;12(5):
pubmed: 32357518
J Clin Invest. 2021 Nov 15;131(22):
pubmed: 34779406
Mol Carcinog. 2020 Jun;59(6):604-617
pubmed: 32212199
Transl Oncol. 2022 Jan;15(1):101267
pubmed: 34773828
Oncology (Williston Park). 2016 Mar;30(3):245-9
pubmed: 26984219
Mol Biomed. 2020 Dec 30;1(1):19
pubmed: 35006434
Nat Rev Cancer. 2010 Apr;10(4):241-53
pubmed: 20300105
Semin Cell Dev Biol. 2011 Oct;22(8):898-905
pubmed: 21821141
Tumour Biol. 2016 Aug;37(8):11375-84
pubmed: 26960831
World J Gastrointest Oncol. 2022 Jan 15;14(1):253-264
pubmed: 35116115
Future Med Chem. 2021 Jan;13(2):117-141
pubmed: 33295810
Cancers (Basel). 2021 Jan 26;13(3):
pubmed: 33530343
Br J Cancer. 2012 Sep 4;107(6):967-76
pubmed: 22892391
Cancers (Basel). 2021 May 12;13(10):
pubmed: 34066040
Mod Pathol. 2021 Jun;34(6):1185-1193
pubmed: 33462368
Onco Targets Ther. 2020 Dec 14;13:12797-12809
pubmed: 33363385
Pathol Res Pract. 2020 Apr;216(4):152863
pubmed: 32098697
Int J Cancer. 2019 Sep 1;145(5):1280-1289
pubmed: 31034097
Int J Cancer. 2022 Jun 1;150(11):1879-1888
pubmed: 35253909
J Urol. 2012 Jun;187(6):2236-42
pubmed: 22503055
Comput Biol Chem. 2019 Dec;83:107155
pubmed: 31706153
Cancers (Basel). 2022 Feb 28;14(5):
pubmed: 35267553
Cytometry B Clin Cytom. 2009 Mar;76(2):79-90
pubmed: 18727058
Cancer. 1990 Feb 1;65(3):433-8
pubmed: 2297633
Pathologe. 2021 Jul;42(4):391-398
pubmed: 34152463

Auteurs

Ria Winkelmann (R)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Am Main, Germany. ria.winkelmann@kgu.de.

Katrin Bankov (K)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Claudia Döring (C)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Jaroslav Cinatl (J)

Dr. Petra Joh Forschungshaus, Frankfurt Am Main, Germany.

Sebastian Grothe (S)

Dr. Petra Joh Forschungshaus, Frankfurt Am Main, Germany.
Institute of Medical Virology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Florian Rothweiler (F)

Dr. Petra Joh Forschungshaus, Frankfurt Am Main, Germany.
Institute of Medical Virology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Martin Michaelis (M)

School of Biosciences, University of Kent, Canterbury, UK.

Christina Schmitt (C)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Peter J Wild (PJ)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Am Main, Germany.
Frankfurt Institute for Advanced Studies (FIAS), Frankfurt Am Main, Germany.

Melanie Demes (M)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Jindrich Cinatl (J)

Dr. Petra Joh Forschungshaus, Frankfurt Am Main, Germany.
Institute of Medical Virology, University Hospital Frankfurt, Frankfurt Am Main, Germany.

Stefan Vallo (S)

Institute of Medical Virology, University Hospital Frankfurt, Frankfurt Am Main, Germany.
Department of Urology, University Hospital Frankfurt, Frankfurt Am Main, Germany.
Urologie an der Zeil, Frankfurt Am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Increased HRD score in cisplatin resistant...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › Increased HRD score in cisplatin resistant...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs du pénis › Increased HRD score in cisplatin resistant...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Increased HRD score in cisplatin resistant...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Uracile › Fluorouracil › Increased HRD score in cisplatin resistant...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Increased HRD score in cisplatin resistant...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Increased HRD score in cisplatin resistant...